These findings are comforting as clinicians can now safely use these agents in patients with metabolic syndrome and those at a higher cardiovascular risk
[3] On the other hand, Tirzepatide distinguishes itself with dual GLP-1 and GIP receptor agonism, achieving HbA1c reductions of up to 2.4% and weight loss of up to 8.8 kg at 15 mg in SURPASS trials
however, their effects on the reproductive system of patients are often overlooked, especially their impact on germ cell cytogenesis, embryonic development, and reproductive system maturation
GLP-1 therapy helps regulate insulin, stabilize blood sugar levels, and reduce fat storage, contributing to better energy levels, mood, and overall well-being
In both trials, the most common side effect was gastrointestinal symptoms, which affected about half of the patients on either dose and about a quarter of patients on the placebo